With new guidance, treatment pathways, and medical advances emerging on a regular basis, the pursuit of knowledge and innovation is a never-ending process for healthcare providers.
For pharmaceutical companies and other healthcare stakeholders, it is imperative that they understand how patient experience and input needs to be captured, contextualised, and applied to t
In a time of increasing cost pressures, limited resource capacity, and heightened demand for new treatments, Health Technology Assessments (HTAs) play a vital role in evaluating whether new
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh